Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial.

Kollmar O, Moussavian MR, Richter S, de Roi P, Maurer CA, Schilling MK

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology4 Mar 2008Cited by 69 (Europe PMC)

PMID18299182DOI10.1016/j.ejso.2008.01.014PepBankPUB-18299182

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, clinical delayed gastric emptying was similar with octreotide and placebo, at approximately 20%.
In plain wordsAfter pancreatic surgery, delayed stomach emptying was similar with octreotide and placebo.
Peptide
Octreotide
Outcome
Direction not reportedClinical delayed gastric emptying
Study
n = 67
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Clinical delayed gastric emptying incidence
≈ 20%
both groups
Source sentences
Summary
DGE measured by clinical signs was similar between both groups studied ( approximately 20% of the patients).
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, randomized, double-blinded, placebo-controlled trial we analyzed the influence of prophylactic octreotide on delayed gastric empting after pancreaticoduodenectomy.
Summary · context
Patients were randomized to the placebo group (n=32) and the octreotide group (n=35).
Report a problemFND-1829918201
02HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, prophylactic octreotide did not reduce postoperative pancreatic fistula incidence versus placebo.
In plain wordsAfter pancreatic surgery, octreotide did not reduce pancreatic fistulas compared with placebo.
Peptide
Octreotide
Outcome
No significant changePostoperative pancreatic fistula
Study
n = 67
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
POPF grade C incidence
≈ 3%
all patients
Source sentences
Summary
POPF grade C occurred in approximately 3% of the patients, although prophylactic treatment of octreotide did not reduce the incidence of POPF.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, randomized, double-blinded, placebo-controlled trial we analyzed the influence of prophylactic octreotide on delayed gastric empting after pancreaticoduodenectomy.
Summary · context
Patients were randomized to the placebo group (n=32) and the octreotide group (n=35).
Report a problemFND-1829918204
03HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, scintigraphy half-time at day 7 was 76.3+/-15.2 minutes with octreotide versus 86.7+/-18.0 with placebo.
In plain wordsAfter pancreatic surgery, stomach-emptying time on imaging was numerically shorter with octreotide than placebo.
Peptide
Octreotide
Outcome
DecreaseGastric scintigraphy half-time at day seven
Study
n = 67
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Gastric scintigraphy T1/2 mean at day 7
76.3 min
octreotide group
Gastric scintigraphy T1/2 SD at day 7
15.2 min
octreotide group
Gastric scintigraphy T1/2 mean at day 7
86.7 min
control group
Gastric scintigraphy T1/2 SD at day 7
18 min
control group
Source sentences
Summary
Gastric scintigraphy (T(1/2)) was 76.3+/-15.2 min in the octreotide group and 86.7+/-18.0 min in controls at day 7, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, randomized, double-blinded, placebo-controlled trial we analyzed the influence of prophylactic octreotide on delayed gastric empting after pancreaticoduodenectomy.
Summary · context
Patients were randomized to the placebo group (n=32) and the octreotide group (n=35).
Report a problemFND-1829918202
04HumanRandomized controlled trialEfficacy outcome
After pancreaticoduodenectomy, breath-test time at day 8 was 65.0+/-6.5 minutes with octreotide versus 67.0+/-5.7 with placebo.
In plain wordsAfter pancreatic surgery, breath-test time was numerically shorter with octreotide than placebo.
Peptide
Octreotide
Outcome
DecreaseHydrogen breath test at day eight
Study
n = 67
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
H2 breath test mean at day 8
65 min
octreotide group
H2 breath test SD at day 8
6.5 min
octreotide group
H2 breath test mean at day 8
67 min
control group
H2 breath test SD at day 8
5.7 min
control group
Source sentences
Summary
The H(2) breath test was 65.0+/-6.5 min in octreotide treatment group and 67.0+/-5.7 min in controls at day 8.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective, randomized, double-blinded, placebo-controlled trial we analyzed the influence of prophylactic octreotide on delayed gastric empting after pancreaticoduodenectomy.
Summary · context
Patients were randomized to the placebo group (n=32) and the octreotide group (n=35).
Report a problemFND-1829918203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.